Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667485 · ClinicalTrials.gov registry record · Phase 1
Rapamycin Plus Bevacizumab in Advanced Cancers
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00667485 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 28 participants.
The verdict
NCT00667485, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.
Interventions
- DRUG Bevacizumab
- DRUG Rapamycin (Tablets)
- DRUG Rapamycin (liquid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667485
The ClinicalTrials.gov registry entry for NCT00667485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00667485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667485 about?
NCT00667485 is a clinical study titled "Rapamycin Plus Bevacizumab in Advanced Cancers". The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.
What is the current status of trial NCT00667485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00667485?
The interventions under investigation include: Bevacizumab (DRUG), Rapamycin (Tablets) (DRUG), Rapamycin (liquid) (DRUG).
Who is sponsoring clinical trial NCT00667485?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.